RESUMO
INTRODUCTION: There are suggestions that virus co-infections may influence the clinical outcome of respiratory virus illness. We performed a systematic review of the literature to summarise the evidence. METHODS: MEDLINE, EMBASE, Ovid and WEB of Science databases, major organisation websites and reference lists of published studies were searched. The quality of studies was assessed using the STROBE tool (von Elm et al., 1) Individual study data was analyzed using odds ratios and 95% confidence intervals as a measure of association between exposure (co-infection), patient outcome and results summarised using forest plots and tables RESULTS: Nineteen (19) studies from all over the world were identified and included in the review. Most of the studies 73.7% (14/19) recruited children ≤ 6 years old. Evidence on the role of co-infection in increasing disease severity was inconclusive. In five out of eight studies, co-infection significantly increased risk of admission to general ward (OR: 2.4, 95% CI: 1.3 - 4.4, p = 0.005; OR: 2.4, 95% CI: 1.1 - 7.7, P = 0.04; OR: 3.1, 95% CI: 2.0 - 5.1, p = <0.001; OR: 2.4, 95% CI: 1.7-3.4, p = <0.0001 and OR: 2.3, 95% CI: 1.1 - 5.1, p = 0.34), one found it did not (OR: 0.59, 95% CI: 0.4 - 0.9, p = 0.02) and the other 2 had insignificant results. Similarly on risk of admission to ICU, some studies found that co-infection significantly increased risk of admission to ICU (OR: 2.9, 95% CI: 1.4 - 5.9, p = 0.004 and OR: 3.0, 95% CI: 1.7 - 5.6, p = <0.0001), whereas others did not (OR: 0.18, 95% CI: 0.05 - 0.75, p = 0.02 and OR: 0.3, 95% CI: 0.2 - 0.6, p = <0.0001). There was no evidence for or against respiratory virus co-infections and risk of bronchiolitis or pneumonia. CONCLUSION: The influence of co-infections on severe viral respiratory disease is still unclear. The observed conflict in outcomes could be because they were conducted in different seasons and covered different years and periods. It could also be due to bias towards the null, especially in studies where only crude analysis was conducted. Future studies should employ stratified analysis.
Assuntos
Doenças Respiratórias/terapia , Doenças Respiratórias/virologia , Criança , Coinfecção , Humanos , Fatores de Risco , Índice de Gravidade de DoençaRESUMO
Merkel cell polyomavirus (MCPyV) was identified originally in association with a rare but aggressive skin cancer, Merkel cell carcinoma. The virus has since been found in the respiratory tract of some patients with respiratory disease. However, the role of MCPyV in the causation of respiratory disease has not been established. To determine the prevalence of MCPyV in 305 respiratory samples from immunocompetent and immunocompromised patients and evaluate their contribution to respiratory diseases, specimens were screened for MCPyV using single, multiplex, or real-time PCR; co-infection with other viruses was examined. Of the 305 samples tested, 10 (3.27%) were positive for MCPyV. The virus was found in two groups of patients: in 6 (2%) nasopharyngeal aspirate samples from children aged 26 days to 7 months who were immunocompetent; and in 4 (1.3%) of nasopharyngeal aspirate samples taken from patients aged 41 to 69 years who were severely immunosuppressed from leukemia or transplant therapy. Both groups had upper or lower respiratory tract infection. Co-infections with other viruses were found in 30% of the MCPyV positive samples. The data present a pattern of infection similar to that seen with the polyomaviruses JC and BK in which the virus is acquired during childhood, probably by the respiratory route. The viruses then establish latency and become reactivated in the event of immunosuppression.
Assuntos
Hospedeiro Imunocomprometido , Poliomavírus das Células de Merkel/classificação , Poliomavírus das Células de Merkel/isolamento & purificação , Infecções por Polyomavirus/epidemiologia , Infecções por Polyomavirus/virologia , Infecções Respiratórias/epidemiologia , Infecções Respiratórias/virologia , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Análise por Conglomerados , Coinfecção/epidemiologia , DNA Viral/química , DNA Viral/genética , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Poliomavírus das Células de Merkel/genética , Pessoa de Meia-Idade , Nasofaringe/virologia , Filogenia , Prevalência , Reação em Cadeia da Polimerase em Tempo Real , Análise de Sequência de DNA , Adulto JovemRESUMO
Electron microscopy (EM), real-time polymerase chain reaction (PCR) and conventional PCR were used to identify viruses associated with infection in 2 transplantation patients. An autologous haematopoietic stem cell, liver and renal transplant recipient was found to be positive for simian virus 40 (SV40). Dual BK virus and SV40 infection was found in a heart and renal transplantation patient. SV40 infection can occur in immunocompromised patients.
Assuntos
Infecções por Polyomavirus/diagnóstico , Vírus 40 dos Símios/isolamento & purificação , Transplantes/efeitos adversos , Infecções Tumorais por Vírus/diagnóstico , Adulto , Vírus BK/isolamento & purificação , Sequência de Bases , DNA Viral/química , DNA Viral/genética , Feminino , Humanos , Hospedeiro Imunocomprometido , Microscopia Eletrônica , Pessoa de Meia-Idade , Dados de Sequência Molecular , Reação em Cadeia da Polimerase , Infecções por Polyomavirus/virologia , Análise de Sequência de DNA , Transplante , Infecções Tumorais por Vírus/virologiaRESUMO
Highly effective glycoconjugate vaccines exist against four of the five major pathogenic groups of meningococci: A, C, W-135, and Y. An equivalent vaccine against group B meningococci (menB) has remained elusive due to the poorly immunogenic capsular polysaccharide. A promising alternative, the investigational recombinant menB (rMenB)- outer membrane vesicle (OMV) vaccine, contains fHBP, NHBA (previously GNA2132), NadA, and outer membrane vesicles (OMVs) from the New Zealand MeNZB vaccine. MenB currently accounts for 90% of meningococcal disease in England and Wales, where the multilocus sequence type (ST) 269 (ST269) clonal complex (cc269) has recently expanded to account for a third of menB cases. To assess the potential cc269 coverage of the rMenB-OMV vaccine, English and Welsh cc269 isolates from the past decade were genetically characterized with respect to fHBP, NHBA, and NadA. All of the isolates harbored fHbp and nhba alleles, while 98% of the cc269 isolates were devoid of nadA. Subvariant profiling of fHbp, nhba, and porA against STs revealed the presence of two broadly distinct and well-defined clusters of isolates, centered around ST269 and ST275, respectively. An additional molecular marker, insertion sequence IS1301, was found to be present in 100% and <2% of isolates of the respective clusters. On the basis of the genetic data, the potential rMenB-OMV coverage of cc269 in England and Wales is high (up to 100%) within both clusters. Expression studies and serum bactericidal antibody assays will serve to enhance predictions of coverage and will augment ongoing studies regarding the significance of IS1301 within the ST269 cluster.
Assuntos
Proteínas de Bactérias/genética , Técnicas de Tipagem Bacteriana , Elementos de DNA Transponíveis , Infecções Meningocócicas/epidemiologia , Infecções Meningocócicas/microbiologia , Neisseria meningitidis/classificação , Neisseria meningitidis/isolamento & purificação , Análise por Conglomerados , Impressões Digitais de DNA , Inglaterra/epidemiologia , Genótipo , Humanos , Infecções Meningocócicas/prevenção & controle , Vacinas Meningocócicas/imunologia , Epidemiologia Molecular , Dados de Sequência Molecular , Neisseria meningitidis/genética , Neisseria meningitidis/imunologia , Análise de Sequência de DNA , Homologia de Sequência , País de Gales/epidemiologiaRESUMO
Post-transplant lymphoproliferative disorder (PTLD) is a rare, serious complication following solid organ transplantation, with an incidence of 2.6 cases per 1000 patient years. Optimal treatment strategies and risk stratifications specific to kidney transplantation are lacking and PTLD mortality remains high. This study investigated survival and prognosis in 89 cases of PTLD presenting over 44 years at Manchester Royal Infirmary. Patient survival following diagnosis was 72% at 6 months, 67% at 1 year and 54% at 3 years. In multivariate analysis, a poorer 3 year survival was associated with acute kidney injury at diagnosis (p = 0.0001), impaired renal function (p = 0.04), early onset (p = 0.02), T cell disease (p = 0.02) and previous treatment with anti-thymocyte globulin (p = 0.04). The inclusion of graft function adds prognostic value to risk stratification and should be explored further. Strategies to improve survival should include timing and choice of immuno-chemotherapy, preparation for dialysis and aggressive surveillance for sepsis and treatment toxicity.
RESUMO
Hepatitis C virus (HCV) is a major cause of chronic hepatitis with liver-related death occurring in 20-25% of patients who develop cirrhosis. Detection of the virus RNA in liver is difficult since viral expression is very low. In situ polymerase chain reaction (PCR) in situ hybridisation (ISH) was developed for detection and localisation of viral RNA in formalin-fixed, paraffin-embedded liver tissue. Nested PCR technology was adapted for in situ use employing primers derived from the 5' end of the HCV genome. Seventeen liver blocks from known HCV-infected patients were examined. Viral RNA was detected in liver from eleven patients using solution phase reverse transcriptase-PCR. Of these positive samples, ten were positive by the in situ method. Positive signal was detected in the cytoplasm of hepatocytes and mononuclear cells. No Kupffer cell or bile duct epithelial positivity was observed. No positive signal was evident in any of the negative controls. A reliable method is described to demonstrate the presence and localisation of HCV RNA in liver tissue using an in situ PCR-ISH assay and it is believed that this will be a valuable tool for the understanding of HCV replication and pathogenesis.
Assuntos
Hepacivirus/isolamento & purificação , Hepatócitos/virologia , Hibridização In Situ/métodos , Fígado/virologia , Reação em Cadeia da Polimerase/métodos , RNA Viral/análise , Hepacivirus/genética , Hepatite C Crônica/virologia , HumanosRESUMO
A phage antibody display library of single chain fragment variable (scFv) was applied to develop anti-HCMV glycoprotein B (gB) and glycoprotein H (gH) neutralising libraries. To enrich for specific scFvs, the phage antibody was panned against cytomegalovirus epitopes derived from the N-terminal part of gB, the C-terminal part of gB and the N-terminal part of gH (NETIYNTTLKYGDV, VTSGSTKD and AASEALDPHAFHLLLNTYGR). A number of clones were differentiated by Bst N1 fingerprinting. After isolation of specific clones against each peptide, the neutralising effect of each clone was assessed by plaque reduction assay. This resulted in the isolation of eight neutralising scFv antibodies with 51-63% neutralising effects. Sequence analysis of three neutralising clones revealed the amino acids specificity changes in heavy and light chains of antibody molecules.
Assuntos
Anticorpos Antivirais/genética , Anticorpos Antivirais/imunologia , Proteínas do Envelope Viral/imunologia , Anticorpos Monoclonais/imunologia , Células Cultivadas , Clonagem Molecular , Infecções por Citomegalovirus/imunologia , Efeito Citopatogênico Viral/imunologia , Ensaio de Imunoadsorção Enzimática/métodos , Humanos , Região Variável de Imunoglobulina/análise , Testes de Neutralização , Biblioteca de Peptídeos , Peptídeos/metabolismo , Proteínas Recombinantes/imunologia , Sensibilidade e EspecificidadeRESUMO
BACKGROUND: There is little information in the literature describing the relationship between posttransplantation lymphoproliferative disorder (PTLD) incidence and presentation with both recipient Epstein-Barr virus (EBV) serostatus and EBV status of PTLD histology, particularly in the late posttransplantation period. METHODS: This study reports the largest UK single-center, single-organ analysis of PTLD to date in a retrospective cohort study of 80 cases occurring in 4189 adult renal transplant recipients. RESULTS: The incidence rate was 2.6 cases per 1000 patient-years (95% confidence interval [95% CI], 2.1-3.2) for PTLD, 1.8 (95% CI, 1.4-2.4) for non-Hodgkin's lymphoma, and 0.2 (95% CI, 0.07-4.2) for Hodgkin's lymphoma. Non-Hodgkin's lymphoma occurred at a rate 7.6 times that of the adult general population in England, whereas the rate for Hodgkin's lymphoma was 5.9 times. The incidence of PTLD was highest during the 10th to 14th posttransplantation years. Early-onset disease was associated with EBV-seronegative recipient status, EBV-positive histology, and the involvement of extranodal sites. PTLD occurring in EBV-seronegative recipients was associated with EBV nuclear antigen antibody deficiency, polymorphic disease, and the involvement of extranodal sites. EBV-negative histology occurred in 32% of cases at a median time to presentation of 109 months. PTLD involving the allograft, central nervous system, and skin was uncommon and occurred late. CONCLUSION: The incidence of PTLD is highest in the late posttransplantation period. Close clinical surveillance and education for transplant recipients is required for the duration of time while immunosuppressed. Failure to detect EBV DNA in blood should not reassure, particularly in patients with symptoms such as abdominal pain, oropharyngeal complaints, neck lumps, and B-symptoms.
Assuntos
Infecções por Vírus Epstein-Barr/epidemiologia , Doença de Hodgkin/epidemiologia , Transplante de Rim/efeitos adversos , Linfoma não Hodgkin/epidemiologia , Transtornos Linfoproliferativos/epidemiologia , Transplante , Adulto , Idoso , Anticorpos Antivirais/sangue , Estudos de Coortes , Comorbidade , DNA Viral/sangue , Infecções por Vírus Epstein-Barr/sangue , Feminino , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/imunologia , Doença de Hodgkin/sangue , Doença de Hodgkin/mortalidade , Humanos , Incidência , Estimativa de Kaplan-Meier , Transplante de Rim/mortalidade , Linfoma não Hodgkin/sangue , Linfoma não Hodgkin/mortalidade , Transtornos Linfoproliferativos/sangue , Transtornos Linfoproliferativos/mortalidade , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Estudos Retrospectivos , Taxa de Sobrevida , Reino Unido/epidemiologiaRESUMO
Invasive disease caused by meningococcal capsular groups A, C, W-135, and Y is now preventable by means of glycoconjugate vaccines that target their respective polysaccharide capsules. The capsule of group B meningococci (MenB) is poorly immunogenic and may induce autoimmunity. Vaccines based on the major immunodominant surface porin, PorA, are effective against clonal epidemics but, thus far, have a limited scope of coverage against the wider MenB population at large. In an alternative approach, the first-generation, investigational, recombinant MenB (rMenB) plus outer membrane vesicle (OMV) (rMenB-OMV) vaccine contains a number of relatively conserved surface proteins, fHBP, NHBA (previously GNA2132), and NadA, alongside PorA P1.4-containing OMVs from the New Zealand MeNZB vaccine. MenB currently accounts for approximately 90% of cases of meningococcal disease in England and Wales. To assess potential rMenB-OMV vaccine coverage of pathogenic MenB isolates within this region, all English and Welsh MenB case isolates from January 2008 (n = 87) were genetically characterized with respect to fHBP, NHBA, NadA, and PorA. Alleles for fHbp, nhba, and porA were identified in all of the isolates, of which 22% were also found to harbor nadA alleles. On the basis of genotypic data and predicted immunological cross-reactivity, the potential level of rMenB-OMV vaccine coverage in England and Wales ranges from 66% to 100%.
Assuntos
Adesinas Bacterianas , Antígenos de Bactérias , Proteínas de Bactérias , Infecções Meningocócicas/prevenção & controle , Vacinas Meningocócicas/imunologia , Neisseria meningitidis Sorogrupo B/genética , Porinas , Adesinas Bacterianas/química , Adesinas Bacterianas/genética , Adesinas Bacterianas/imunologia , Alelos , Sequência de Aminoácidos , Antígenos de Bactérias/química , Antígenos de Bactérias/genética , Antígenos de Bactérias/imunologia , Proteínas de Bactérias/química , Proteínas de Bactérias/genética , Proteínas de Bactérias/imunologia , Reações Cruzadas/imunologia , Inglaterra/epidemiologia , Genótipo , Humanos , Infecções Meningocócicas/epidemiologia , Infecções Meningocócicas/imunologia , Infecções Meningocócicas/microbiologia , Vacinas Meningocócicas/administração & dosagem , Vacinas Meningocócicas/genética , Dados de Sequência Molecular , Neisseria meningitidis Sorogrupo B/classificação , Neisseria meningitidis Sorogrupo B/imunologia , Neisseria meningitidis Sorogrupo B/isolamento & purificação , Reação em Cadeia da Polimerase , Porinas/química , Porinas/genética , Porinas/imunologia , Alinhamento de Sequência , Análise de Sequência de DNA , Vacinas Sintéticas/administração & dosagem , Vacinas Sintéticas/imunologia , País de Gales/epidemiologiaRESUMO
Since its discovery, human parvovirus B19 has been linked with a broad spectrum of clinical syndromes. An aetiological role for the virus has been confirmed in erythema infectiosum, transient aplastic crisis, persistent infection manifesting as pure red cell aplasia in immunocompromised persons, non-immune hydrops fetalis and arthritis. Less commonly recognised, but receiving increasing attention recently, are the neurological manifestations, a variety of which have been described in patients with either clinically diagnosed or laboratory confirmed B19 infection. The purpose of this review is to summarise present knowledge of B19, its known and potential pathogenic mechanisms and its association with human diseases, particularly those with neurological manifestations. The outcome of the review supports an aetiological role of the virus in neurological disease. However, the pathogenesis remains unknown and elucidating this is a priority.